Ascendis Pharma Aktie
WKN DE: A14M6X / ISIN: US04351P1012
04.09.2024 22:48:00
|
Why Ascendis Pharma Stock Tumbled by 11% Today
An earnings miss and sharply reduced guidance for its ONE commercialized product doomed Ascendis Pharma (NASDAQ: ASND) to a bad Wednesday on the stock market. The biotech's shares fell by more than 11% in price after it divulged its latest set of quarterly results. By comparison, the bellwether S&P 500 index suffered a relatively modest drop of 0.2%.Ascendis, a biotech based in Denmark, took the wraps off its second quarter soon after market hours on Tuesday. The company posted revenue of slightly under 36 million euros ($40 million) for the period, a figure that was well down from the more than 47 million euros ($52 million) it earned in the same quarter of 2023. More encouragingly, Ascendis managed to narrow its net loss over that stretch of time. Its deficit was a bit more than 109 million euros ($120 million), which equates to 1.91 euros ($2.11) per share. The year-ago shortfall was almost 122 million euros ($135 million).Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Ascendis Pharma (spons. ADRs)mehr Nachrichten
11.02.25 |
Ausblick: Ascendis Pharma (spons ADRs) legt Quartalsergebnis vor (finanzen.net) |
Analysen zu Ascendis Pharma (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Ascendis Pharma (spons. ADRs) | 138,00 | 22,12% |
|